protexam tests - for a long and healthy life
Healthcare redefined: Products for private customers
In a time when awareness of personal health is constantly growing, protexam GmbH offers innovative solutions for the early detection of diseases. Our advanced proteomic analysis makes it possible to identify potential health risks precisely and early, long before symptoms appear. Rely on a scientifically sound method to proactively monitor and protect your health.
The future of diagnostics: Proteomic analysis for your health
Our core competence lies in the highly precise analysis of protein patterns in urine. Each of these patterns is as unique as a fingerprint and provides detailed information about your current state of health. By using artificial intelligence, we are able to detect deviations that may indicate the onset of diseases.
Your advantages at a glance:
- Early detection: Identify health risks before they become a serious problem.
- Non-invasive: A simple urine sample is sufficient for a comprehensive analysis.
- Precision: State-of-the-art technology and artificial intelligence ensure highly reliable results.
- Prevention: Take targeted measures to maintain your health based on sound data.
Recognize chronic diseases and cancer and act proactively!
HCU test
(Heart Check-Up)
Cardiovascular diseases often develop over many years and frequently go undetected in their early stages. Risk factors such as high blood pressure, elevated blood lipid levels, or reduced physical capacity can be early indicators of a possible cardiovascular disease.
An early assessment of individual risk can help to initiate preventive measures and to detect existing diseases early.
The protexam HCU test is a urine-based biomarker test based on modern proteomic analysis. It was developed to provide indications of the presence of cardiovascular diseases – such as coronary artery disease or functional changes of the heart.
The test can serve as supplementary information to existing diagnostics and help to better assess individual risks and plan further diagnostic or therapeutic steps.
Scientific basis
The biomarkers underlying the test have been investigated in several clinical studies. The analyses are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry), an established method in proteomics research.
Selected publications:
- Delles C, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens. 2010, 28, 2316–2322.
- Kuznetsova T, Mischak H, Mullen W, Staessen JA. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J. 2012, 33(18):2342-50.
- Campbell RT, et al. The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Fail. 2020, 7(4):1595-1604.
KCU test
(Kidney Check-Up)
Chronic kidney diseases often develop gradually over a long period. In early stages, they often go unnoticed as kidney function gradually declines.
Early detection of possible changes can help to slow the progression of the disease and to initiate appropriate therapeutic measures in a timely manner.
The protexam KCU test is a urine-based biomarker test based on modern proteomic analysis. It was developed to provide early indications of changes in kidney function – even before classic laboratory parameters become clearly abnormal.
The test can better assess individual risks in order to plan preventive measures early.
Scientific basis
The underlying biomarkers were investigated in several clinical studies. The analyses are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry), an established method in proteomics research.
Selected publications:
- Good DM, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9(11):2424-37.
- Pontillo C, et al. A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol Dial Transplant. 2017, 32(9):1510-1516.
- Pontillo C, et al. Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. Kidney Int Rep 2017, 2(6):1066-1075.
CRS test
(CardioRenal Status)
Patients with diabetes or high blood pressure have an increased risk of heart and kidney disease. Early assessment of individual risk can help initiate preventive measures and detect potential complications in a timely manner.
Routine check-ups with a general practitioner or diabetologist often only detect advanced changes. For example, a standard test like albuminuria only shows changes when kidney function is already impaired. Similarly, cardiological tests for heart failure or arterial calcification are often only performed when there is a suspicion of illness.
The protexam CRS test is a urine-based biomarker test that can provide indications of possible kidney and cardiovascular diseases at an earlier stage.
Composition of the CRS test
The CRS test combines two established protexam tests:
- KCU test: Early detection of changes in kidney function
- HCU test: Early detection of increased risk of heart attack, heart failure or arteriosclerotic changes
This delivers the CRS test a supplementary risk assessment that can support the decision on preventive measures or further diagnostics.
Scientific basis
The biomarker-based tests are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry) and have been validated in several clinical studies.
Selected publications:
- Good DM, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9(11):2424-37.
- Tofte N, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomized placebo-controlled trial. Lancet Diabetes Endocrinol. 2020, 8(4):301-312.
- Delles C et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens. 2010, 28, 2316-2322.
- Kuznetsova T, Mischak H, Mullen W, Staessen JA. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J. 2012, 33(18):2342-50.
BCU test
(Bladder Check-Up)
Symptoms such as blood in the urine, frequent bladder infections, or increased urinary frequency are not usually associated with bladder cancer. Nevertheless, an early assessment can be helpful in better evaluating individual risk.
The protexam BCU test is a urine-based biomarker test based on modern proteomic analysis. It provides indications of tissue changes in the bladder and can help assess the risk of bladder cancer – even before classic methods such as ultrasound or microscopic urine examinations can reliably detect changes.
Through the supplementary information of the
BCU tests Unnecessary cystoscopies can be avoided, which can be associated with risks such as injuries to the urethra, bladder or sphincter muscle.
BSM test
(Bladder Status Monitoring)
In cases of superficial bladder cancer, treatment that preserves the bladder is possible. However, there is a risk of recurrence after treatment.
CCystoscopies are typically performed every three months for monitoring purposes. The protexam BSM test is a urine-based biomarker test that can be used as a supplementary monitoring tool. It helps assess the risk of recurrence and can help reduce the need for invasive follow-up examinations.
Scientific basis
The biomarker-based tests were investigated and validated in multicenter clinical trials. The analyses are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry).
Selected publications:
- Mengual L, et al. A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnosis and monitoring. Br J Cancer 2022, 127(11):2043-2051.
- Franzi M, et al. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clin Cancer Res 2016, 22(16):4077-86.
PCU test
(Prostate Check-Up)
An elevated PSA level alone is not a reliable indicator of prostate cancer. Studies show that the majority of elevated PSA levels are due to other, non-malignant causes.
Before further diagnostic procedures such as a prostate biopsy, an additional, non-invasive examination may be useful. Biopsies are established procedures, but – like any medical intervention – they can be associated with risks and side effects.
The protexam PCU test is a urine-based biomarker test that utilizes advanced proteomic analysis. It can help better assess an individual’s risk of prostate cancer and guide decisions regarding further diagnostic steps.
Further information can be found at:
PSM test
(Prostata Status Management)
Not every diagnosed prostate cancer requires immediate treatment. A significant proportion of tumors grow slowly and can be monitored through active surveillance.
The challenge lies in distinguishing clinically relevant (aggressive) tumors from less aggressive ones.
The protexam PSM test is based on the analysis of specific protein patterns in urine and was developed to provide information about the aggressiveness of prostate cancer. It can help inform treatment decisions and enable a personalized treatment strategy.
Scientific basis
The underlying biomarkers were investigated and validated in several clinical studies. The analyses are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry), an established method in proteomics research.
Selected publications:
- Nigusu Jobre K, et al. Prospective validation of a urine-based proteomic test for predicting clinically significant prostate cancer in biopsy-naive patients. Research Square, 2026, doi:10.21203/rs.3.rs-8933198/v1.
- Franzi M, et al. Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI Pathway.
- Pathobiology 2025, 92(2):99-108.
- Franzi M, et al. Mass spectrometry-based biomarkers to detect prostate cancer: A multicentric study based on non-invasive urine collection without prior intervention. Cancers (Basel) 2023, 15:1166.
- Franzi M, et al. Validation of diagnostic nomograms based on CE-MS urinary biomarkers to distinguish clinically significant prostate cancer. World J Urol. 2022, 40(9):2195-2203.
- Franzi M, et al. CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. Br J Cancer 2019, 120(12):1120-1128.
xCoV test
(severe COVID-19 case)
In cases of SARS-CoV-2 infection, some patients develop a more severe illness that may require intensive care. Early risk assessments can help to initiate appropriate therapeutic measures in a timely manner.
The protexam xCoV test This is a urine-based biomarker test that provides information about an individual's risk of a severe course of COVID-19. The test is based on endogenous, human biomarkers and is therefore independent of the virus variant.
It can serve as supplementary information to help make early decisions about preventive or therapeutic measures together with medical professionals.
Further information can be found at:
Scientific basis
The biomarkers of xCoV tests These factors were investigated in clinical studies and show a significant association with the course of COVID-19. The analyses are based on CE-MS technology (capillary electrophoresis coupled with mass spectrometry).
Selected publications:
- Wendt R, et al., the CRIT-Cov-U investigators. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine 2021, 36:100883.
- Staessen JA, et al., the CRIT-Cov-U investigators. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study. Lancet Digit Health 2022, 4(10):e727-e737.
Important NOTE
The tests provide a risk assessment and do not replace a medical diagnosis. The results should always be interpreted in conjunction with other clinical findings and in consultation with a doctor.